.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Daiichi Sankyo
Federal Trade Commission
Boehringer Ingelheim
Chubb
Farmers Insurance
Fuji
Mallinckrodt
McKinsey
McKesson

Generated: December 17, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Germany Patent: 103 36 400

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Purdue Pharma LpHYSINGLAhydrocodone bitartrateTABLET, EXTENDED RELEASE;ORAL206627-001Nov 20, 2014RXYesYes► Subscribe► SubscribeYMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpHYSINGLAhydrocodone bitartrateTABLET, EXTENDED RELEASE;ORAL206627-002Nov 20, 2014RXYesNo► Subscribe► SubscribeYMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpHYSINGLAhydrocodone bitartrateTABLET, EXTENDED RELEASE;ORAL206627-003Nov 20, 2014RXYesNo► Subscribe► SubscribeYMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpHYSINGLAhydrocodone bitartrateTABLET, EXTENDED RELEASE;ORAL206627-004Nov 20, 2014RXYesNo► Subscribe► SubscribeYMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpHYSINGLAhydrocodone bitartrateTABLET, EXTENDED RELEASE;ORAL206627-005Nov 20, 2014RXYesNo► Subscribe► SubscribeYMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpHYSINGLAhydrocodone bitartrateTABLET, EXTENDED RELEASE;ORAL206627-006Nov 20, 2014RXYesNo► Subscribe► SubscribeYMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpHYSINGLAhydrocodone bitartrateTABLET, EXTENDED RELEASE;ORAL206627-007Nov 20, 2014RXYesNo► Subscribe► SubscribeYMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-001Aug 25, 2011RXYesNo► Subscribe► SubscribeYRELIEF OF MODERATE TO SEVERE CHRONIC PAIN
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-001Aug 25, 2011RXYesNo► Subscribe► SubscribeYMANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-002Aug 25, 2011RXYesNo► Subscribe► SubscribeYRELIEF OF MODERATE TO SEVERE CHRONIC PAIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist